Fibronostics is an biotech company AI-based working on liver diagnosis solutions. During my tenure, my core responsibilities were: • Engineered and implemented an ERP system by leveraging a CRM software: achieved a comprehensive end-to-end system facilitating seamless interaction among various internal functions (sales, operations, finance, IT, and human resources)• Provided the directional board with data analytics that will facilitate budgeting, strategic and operational decision-making• Spearheaded training and initiatives resulting in a forecasted

Ampersand Capital is a Private Equity firm (€3.4b AUM) with an investment focus on healthcare subcategories.During my tenure at Ampersand, my core responsibilities were:• Target identification and qualification of ~20 companies per week reporting periodically to the Investment Committee• Analysis of a biotech company focusing on the development of stem cells collected from deer’s umbilical cord• Market research focusing on the firm’s 4 investment verticals within the Asian Pacific market

During my tenure at PWC, my core responsibilities were:• Daily communication with the CFO of an international consumer goods company and internal reporting • Diagnosed and optimized post-M&A integration problems of different acquisitions at the group level: fostered efficiency through operations solutions and solved communication issues between different departments of the company• Assessed problems in the current company organization by using Qualtrics and one-to-one interviews

Eurazeo is an alternative investment firm based in Paris(€35b AUM).During my tenure, my core responsibilities were:Syndicated 4 co-investment opportunities along different investment strategies (private debt, growth, and mid-large buyout)• Examined strategic SPV structures solutions: analyzed, compared, and developed alternative fundraising structures (Collateral Fund Obligation, Rated Feeder)• Evaluated two competitive selection processes for secondary transactions advisors: analyzed and compared the proposed solutions, the current market conditions, and the fit with Eurazeo’s strategy